当前位置:首页>>博士后之家>>国外博士后招聘>>正文内容

法国巴黎B细胞/浆细胞博后职位

2017年10月16日
来源:知识人网
摘要:

Team “Immunity in Health and Disease”
Institut Necker Enfants Malades, Paris, France

Our team is investigating the cellular and molecular mechanisms implicated in autoimmune and infectious diseases. We have a long-standing focus on the investigation of the role of B cells as suppressors and drivers of immunity through the production of cytokines. We previously found that B cells could regulate immunity through the provision of IL-10 and IL-35 (Nature Immunology 2002, Immunity 2010, Nature 2014), and established that the major B cell subsets producing these cytokines in vivo were two distinct subsets of antibody-secreting cells (Immunity 2010, Nature 2014). We recently identified a marker that specifically identifies IL-10-expressing plasmocytes (submitted), and used this key to generate mice with constitutive and inducible ablation of IL-10-expressing plasmocytes. These mice are available for characterization in various disease models.

The project will additionally involve a translation facet to look for the counterpart of these novel subsets in human, in various situations of health and disease. The project will use a combination of molecular and cellular approaches.

The Institut Necker Enfants Malades (INEM) provides with its two departments in immunology and cellular biology, and its intimate partnership with the IMAGINE institute, an excellent environment to conduct these studies. The laboratory “Immunity in Health and Disease” is within the Necker-Enfants Malades Hospital at the interface between fundamental and clinical research, and the long-term goal of the project is to derive tools useful in the clinic.

The positions are funded by a European Research Council (ERC) grant.

The post-doc candidate should have a strong track record in the field of cellular immunology, or molecular biology. Expertise in experimental models of autoimmunity is highly welcome.

The PhD student should be highly motivated.

The positions are open. Salary will be according to experience following INSERM regulation.